


CONSOLIDATED FINANCIAL STATEMENTS 2017

Overview of the major consolidated companies	32
Consolidated balance sheet	34
Consolidated profit and loss statement	35
Cash flow statement	36
Statement of changes in group equity	37
Notes to the consolidated financial statements	38
Independent auditor's report	60

OVERVIEW OF THE MAJOR CONSOLIDATED COMPANIES



- D** Distribution
- P** Production
- R** Research and Development

*Sole, personally liable, managing shareholder: Boehringer AG

C. H. BOEHRINGER SOHN
GRUNDSTÜCKSVRWALTUNG GMBH & CO. KG

BOEHRINGER INGELHEIM
AUSLANDSBETEILIGUNGS GMBH

ARGENTINA D R

Boehringer Ingelheim S.A.,
Buenos Aires

AUSTRALIA D

Boehringer Ingelheim Pty. Ltd.,
North Ryde

BRAZIL D P

Boehringer Ingelheim do Brasil
Química e Farmaceutica Ltda.,
São Paulo
Solana Agro Pecuaria Ltda.,
Arapongas

CANADA D

Boehringer Ingelheim
(Canada) Ltd., Burlington

CHILE D

Boehringer Ingelheim Ltda.,
Santiago de Chile

CHINA D P

Boehringer Ingelheim Shanghai
Pharmaceuticals Co. Ltd., Shanghai
Boehringer Ingelheim (China)
Investment Co. Ltd., Shanghai
Boehringer Ingelheim Vetmedica
(China) Co. Ltd., Shanghai
Boehringer Ingelheim Animal Health
Operations (China) Co. Ltd., Taizhou

COLOMBIA D P

Boehringer Ingelheim S.A.,
Bogotá

DENMARK D P

Boehringer Ingelheim
Danmark A/S, Copenhagen

ECUADOR D

Boehringer Ingelheim del Ecuador
Cia. Ltda., Quito

FRANCE D P

Boehringer Ingelheim
France S.A.S., Paris

GREECE D P

Boehringer Ingelheim Ellas AE,
Athens

INDIA D

Boehringer Ingelheim
India Private Ltd., Mumbai

INDONESIA D P

PT Boehringer Ingelheim
Indonesia, Jakarta

IRELAND D

Boehringer Ingelheim
Ireland Limited, Dublin

ITALY D P R

Boehringer Ingelheim
Italia S.p.A., Reggello
Bidachem S.p.A.,
Fornovo S. Giovanni

JAPAN D P R

Nippon Boehringer Ingelheim
Co. Ltd., Tokyo
Boehringer Ingelheim
Vetmedica Japan Co. Ltd.,
Tokyo
Boehringer Ingelheim
Seiyaku Co. Ltd., Yamagata
Boehringer Ingelheim
Japan, Inc., Tokyo

MEXICO D P R

Boehringer Ingelheim
Promeco S.A. de C.V.,
Mexico City
Boehringer Ingelheim Vetmedica,
S.A. de C.V., Guadalajara

THE NETHERLANDS D P

Boehringer Ingelheim B.V., Alkmaar
Boehringer Ingelheim Animal Health
Operations B.V., Alkmaar

NEW ZEALAND D

Boehringer Ingelheim
(N.Z.) Ltd., Auckland

PORTUGAL D

Boehringer Ingelheim Lda., Lisbon
Unifarma Lda., Lisbon

SINGAPORE D

Boehringer Ingelheim
Singapore Pte. Ltd., Singapore

SOUTH AFRICA D

Boehringer Ingelheim (Pty.) Ltd.,
Randburg
Ingelheim Pharmaceuticals (Pty.)
Ltd., Randburg

SOUTH KOREA D

Boehringer Ingelheim Korea Ltd.,
Seoul

SPAIN D P

Boehringer Ingelheim
España S.A., Barcelona
Boehringer Ingelheim S.A., Barcelona
Europharma S.A., Barcelona
Laboratorios Fher S.A., Barcelona

SWEDEN D

Boehringer Ingelheim AB, Stockholm

SWITZERLAND D

Boehringer Ingelheim
(Schweiz) GmbH, Basel

TAIWAN D

Boehringer Ingelheim
Taiwan Ltd., Taipei

THAILAND D

Boehringer Ingelheim
(Thai) Ltd., Bangkok

TURKEY D

Boehringer Ingelheim Ilac
Ticaret A.S., Istanbul

UNITED KINGDOM D

Boehringer Ingelheim Ltd.,
Bracknell

USA D P R

Boehringer Ingelheim Corp.,
Ridgefield, Connecticut
Boehringer Ingelheim
Pharmaceuticals, Inc.,
Ridgefield, Connecticut
Boehringer Ingelheim
USA Corporation,
Ridgefield, Connecticut
Boehringer Ingelheim
Vetmedica, Inc.,
St. Joseph, Missouri
Boehringer Ingelheim
Fremont, Inc.,
Fremont, California

C. H. Boehringer Sohn AG & Co. KG, Ingelheim

CONSOLIDATED BALANCE SHEET

Assets (in millions of EUR)	Notes ¹⁾	31.12.2017	31.12.2016
Intangible assets	(4.1)	5,372	550
Tangible assets	(4.2)	3,867	3,045
Financial assets	(4.3)	5,830	6,092
Fixed assets		15,069	9,687
Inventories	(4.4)	3,087	2,610
Accounts receivable and other assets	(4.5)	4,506	4,083
Securities		0	402
Cash and cash equivalents		3,071	6,603
Current assets		10,664	13,698
Prepaid expenses		334	334
Deferred taxes		2,307	2,420
Exceeding amount of plan assets		12	0
Total assets		28,386	26,139
Liabilities and equity (in millions of EUR)	Notes ¹⁾	31.12.2017	31.12.2016
Shareholders' capital		178	178
Group reserves		10,868	11,220
Balance sheet currency conversion difference		- 388	- 71
Equity attributable to the parent company		10,658	11,327
Non-controlling interests		- 1	0
Group equity		10,657	11,327
Difference from capital consolidation		1,729	52
Provisions	(4.6)	12,728	11,937
Accounts payable and loans	(4.7)	2,004	1,984
Liabilities		14,732	13,921
Deferred charges		514	543
Deferred taxes		754	296
Total liabilities and equity		28,386	26,139

¹⁾ For explanations, see relevant section in the Notes to the consolidated financial statements.

C. H. Boehringer Sohn AG & Co. KG, Ingelheim

CONSOLIDATED PROFIT AND LOSS STATEMENT

(in millions of EUR)	Notes ¹⁾	2017	2016
Net sales	(5.1)	18,056	15,850
Changes in finished goods and work in process		- 291	198
Other own work capitalised		16	10
Other operating income	(5.2)	3,411	2,306
Total revenues		21,192	18,364
Cost of materials	(5.3)	- 3,474	- 2,643
Personnel expenses	(5.4)	- 4,934	- 4,570
Amortisation of intangible assets and depreciation of tangible assets	(5.5)	- 963	- 620
Other operating expenses	(5.6)	- 8,334	- 7,659
Operating income		3,487	2,872
Financial income	(5.7)	- 330	- 76
Holding income	(5.8)	- 301	- 4
Income before taxes		2,856	2,792
Income taxes ²⁾	(5.9)	- 3,085	- 943
Income after taxes		- 229	1,849
Net loss/income	(5.10)	- 229	1,849
Non-controlling interests		6	4
Group loss/profit		- 223	1,853

¹⁾ For explanations, see relevant section in the Notes to the consolidated financial statements.

²⁾ Due to legal requirements the disclosure of the shareholders' personal taxes arising from consolidated business activities as tax expenses is not allowed. These taxes are shown as withdrawals from the group reserves.

C. H. Boehringer Sohn AG & Co. KG, Ingelheim

CASH FLOW STATEMENT

(in millions of EUR)	2017
Income after taxes (including third-party share)	- 229
Amortisation of intangible assets and depreciation of tangible assets ¹⁾	963
Change in provisions for pensions	56
Change in other provisions	- 255
Other non-cash income and expenses	610
Gain/loss on disposals of fixed assets	- 6
Change in inventories	305
Change in accounts receivable and other assets not related to investing or financing activities	0
Change in trade accounts payable and other liabilities not related to investing or financing activities	- 60
Interest income/interest expenses (net)	45
Other income from investments	- 12
Income/expenses of extraordinary magnitude or significance	- 1,006
Income taxes	3,085
Cash receipts of extraordinary magnitude or significance	255
Income taxes paid	- 1,127
Cash flow from operating activities	2,624
Investments in intangible assets	- 151
Investments in tangible assets	- 872
Investments in non-current financial assets ¹⁾	- 30
Investments in consolidated companies	- 4,299
Proceeds from disposals of intangible assets	25
Proceeds from disposals of tangible assets	25
Proceeds from disposals of non-current financial assets ¹⁾	9
Cash receipts of extraordinary magnitude or significance	1,125
Interest received	20
Income from dividends	12
Income taxes paid due to sale of businesses	- 979
Cash flow from investing activities	- 5,115

C. H. Boehringer Sohn AG & Co. KG, Ingelheim

CASH FLOW STATEMENT

(in millions of EUR)	2017
Cash receipts from grants	5
Interest paid	-65
Cash payment to owners of parent entity	-198
Cash repayments of loans	-948
Cash flow from financing activities	-1,206
Change in liquid funds from cash relevant transactions	-3,697
Changes in liquid funds due to change of consolidated companies	273
Changes in liquid funds due to exchange rate movements	-435
Financial funds²⁾ as of 1.1.	11,989
Financial funds²⁾ as of 31.12.	8,130

¹⁾ Excl. fixed-asset securities²⁾ Liquid funds, securities within fixed and current assets

(+) = source of funds, (-) = use of funds

STATEMENT OF CHANGES IN GROUP EQUITY

(in millions of EUR)	Shareholders' capital ¹⁾	Group reserves ²⁾	Balance sheet currency conversion difference	Equity attributable to the parent company	Non-controlling interests	Group equity
Balance as of 31.12.2015	178	9,515	-94	9,599	4	9,603
Withdrawals	0	-152	0	-152	0	-152
Net income	0	1,853	0	1,853	-4	1,849
Other changes	0	4	0	4	0	4
Currency effects	0	0	23	23	0	23
Balance as of 31.12.2016	178	11,220	-71	11,327	0	11,327
Withdrawals	0	-145	0	-145	0	-145
Net loss	0	-223	0	-223	-6	-229
Changes in consolidated companies	0	16	-21	-5	5	0
Currency effects	0	0	-296	-296	0	-296
Balance as of 31.12.2017	178	10,868	-388	10,658	-1	10,657

¹⁾ The shareholders' capital consists of the equity of C. H. Boehringer Sohn AG & Co. KG and C. H. Boehringer Sohn Grundstücksverwaltung GmbH & Co. KG. The shareholders' capital consists only of the limited partner's capital contribution.²⁾ The shareholders' personal taxes arising from consolidated business activities are shown as withdrawals from the group reserves. As of 31 December 2017 a negative capital account of one limited partner with the amount of EUR 8 million (previous year: EUR 6 million) was shown as a net item within the group reserves. The liability of this limited partner reinstated in the amount of EUR 10,000.